Company Description
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States.
Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer.
The company also focuses on the clinical program in indications, such as investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, metastatic triple negative breast cancer, and chronic myelomonocytic leukemia; CRDF-004, a Phase 2 open-label randomized multi-center clinical trial of onvansertib in combination with FOLFIRI and bevacizumab or FOLFOX and bevacizumab for the treatment of patients confirmed metastatic and unresectable colorectal cancer in patients with a KRAS or NRAS mutation; and TROV-054, a Phase 1b/2 single-arm clinical trial in KRAS-mutated metastatic colorectal cancer.
The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012.
Cardiff Oncology, Inc. was founded in 1999 and is headquartered in San Diego, California.
| Country | United States |
| Founded | 1999 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 31 |
| CEO | Mani Mohindru |
Contact Details
Address: 11055 Flintkote Avenue San Diego, California 92121 United States | |
| Phone | 858 952 7570 |
| Website | cardiffoncology.com |
Stock Details
| Ticker Symbol | CRDF |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 1213037 |
| CUSIP Number | 14147L108 |
| ISIN Number | US14147L1089 |
| Employer ID | 27-2004382 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Mani Mohindru Ph.D. | Interim Chief Executive Officer and Director |
| Brigitte Lindsay | Chief Accounting Officer |
| Dr. Tod Smeal Ph.D. | Chief Scientific Officer |
| Elizabeth Anderson | Vice President of Finance and Administration |
| Dr. Roger Sidhu M.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 25, 2026 | 8-K | Current Report |
| Feb 24, 2026 | 8-K | Current Report |
| Feb 24, 2026 | 10-K | Annual Report |
| Jan 27, 2026 | 8-K | Current Report |
| Nov 6, 2025 | 8-K | Current Report |
| Nov 6, 2025 | 10-Q | Quarterly Report |
| Aug 28, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Aug 14, 2025 | SCHEDULE 13G/A | Filing |
| Jul 29, 2025 | 8-K | Current Report |
| Jul 29, 2025 | 10-Q | Quarterly Report |